Phase 2a clinical trials

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Bio & Pharma President of Latvia visits S.Korea's Daan Cancer Lab

Daan Cancer Laboratory under Severance Hospital said on Thursday it signed a memorandum of understanding (MOU) with the Latvian government to streng...

Korean startups Mediaiplus aims to be the Amazon of clinical trials

Mediaiplus Inc., South Korea’s only provider of data analytics and contract research organization (CRO) matching services for clinical trials,...

Tech, Media & Telecom LG’s telecom unit looks to lure foreigners with more K-pop-themed shops

LG Uplus Corp., South Korea’s No. 3 mobile carrier, is set to lure foreign customers by opening K-pop-themed stores in the country's major sho...

Bio & Pharma Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...

Construction SGC E&C secures $92 mn chemical plant project in Malaysia

South Korea's SGC eTEC E&C Co. announced on Monday that it secured an additional chemical plant construction project in Malaysia worth 127.3 bil...

Leadership & Management AI to drive Mirae Asset's next-phase growth: chairman

Mirae Asset Group is a pioneer in South Korea’s mutual fund industry. It launched the country’s first equity mutual fund in the wake of ...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Korean chipmakers Samsung gains upper hand vs Netlist in $303 million patent dispute

Samsung Electronics Co. has taken the upper hand in its ongoing legal battle against Netlist Inc. over memory chip module patent infringement allega...

Bio & Pharma Global quest to find modern elixirs enters new chapter

NEW YORK/ BOSTON – Longevity has long been the dream of humankind. China’s first emperor Qin Shi Huang was obsessed with finding magic e...

Artificial intelligence Lunit gets court approval for Volpara acquisition in New Zealand

South Korean medical AI company Lunit announced on Thursday that it received the first approval from the High Court of New Zealand for its plan to a...

Tech, Media & Telecom SK Telecom to enter Australian pet clinics market in H1

South Korea’s SK Telecom Co. announced on Tuesday that it has signed a commercial contract with ATX Medical Solutions, Australia's largest m...

Bio & Pharma Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar

South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...

Bio & Pharma LG Chem to start phase 3 for head, neck cancer drug in US

South Korea’s LG Chem Ltd. announced on Wednesday that its US-based subsidiary Aveo Pharmaceuticals will start Phase 3 clinical trials for its...

Bio & Pharma JW Pharma takes gout drug Epaminurad to Malaysia for phase 3

South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...

Bio & Pharma LG Chem out-licenses obesity drug candidate to US firm

LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...

Bio & Pharma MedPacto gets FDA OK for colorectal cancer drug clinical trial

South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...

Bio & Pharma CGBio gets FDA approval for Novosis Putty

South Korea's bio-regenerative medical firm CGBio announced on Tuesday that its Novosis Putty has been designated as a breakthrough device by the US...

Upcoming IPOs Peter Thiel-backed D&D Pharmatech gets preliminary nod for IPO

South Korean clinical-stage biotech D&D Pharmatech Inc. has won approval from the Korea Exchange’s preliminary review for listing on the j...

Electronics LG Elec launches new medical monitor

LG Electronics Inc. unveiled a new medical monitor on Wednesday. This monitor boasts high brightness suitable for both clinical and diagnostic purpo...

Bio & Pharma HK inno.N reveals differentiated clinical results for K-CAB

South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophag...

Bio & Pharma SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine

South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial ...

Bio & Pharma Celltrion applies for approval in Europe for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...

Bio & Pharma NKMax to perform first tests on dementia cell therapy in US

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

Bio & Pharma Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved

South Korea’s Hanmi Pharmaceutical Co. on Monday said the Ministry of Food and Drug Safety approved Phase 3 clinical trials for the company&...

Bio & Pharma Humedix gets gov't OK for trials of dementia candidate drug

South Korea’s Humedix Co., a developer of biological and pharmaceutical products, on Tuesday said it received approval from the Ministry of Fo...

Bio & Pharma NKMax's US subsidiary listed on Nasdaq

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

Bio & Pharma JW Pharma to conduct Phase 3 trials in Thailand for gout treatment

South Korea's JW Pharmaceutical Corp. on Thursday said it received approval from Thailand's Food and Drug Administration to conduct Phase 3 clinical...

Bio & Pharma Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials

Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...